Literature DB >> 34050731

Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers.

Stéphane Marot1, Isabelle Malet1, Valentin Leducq1, Basma Abdi1, Elisa Teyssou1, Cathia Soulie1, Marc Wirden1, Christophe Rodriguez2,3, Slim Fourati2,3, Jean-Michel Pawlotsky2,3, David Boutolleau1, Sonia Burrel1, Vincent Calvez1, Anne-Geneviève Marcelin1, Aude Jary1.   

Abstract

There are concerns about neutralizing antibodies' (NAbs') potency against severe acute respiratory syndrome coronavirus 2 variants. Despite decreased NAb titers elicited by BNT162b2 vaccine against VOC202012/01 and 501Y.V2 strains, 28/29 healthcare workers (HCWs) had an NAb titer ≥1:10. In contrast, 6 months after coronavirus disease 2019 mild forms, only 9/15 (60%) of HCWs displayed detectable NAbs against 501Y.V2 strain.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; SARS-CoV-2 variants; neutralizing antibodies; vaccine

Mesh：

Substances：

Year:  2022        PMID： 34050731      PMCID： PMC8244299          DOI： 10.1093/cid/ciab492

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  6 in total

Review 1.  Adaptive Immune Responses and Immunity to SARS-CoV-2.

Authors:  Dragan Primorac; Kristijan Vrdoljak; Petar Brlek; Eduard Pavelić; Vilim Molnar; Vid Matišić; Ivana Erceg Ivkošić; Marijo Parčina
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

2.  Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks.

Authors:  Hubert Blain; Edouard Tuaillon; Lucie Gamon; Amandine Pisoni; Stéphanie Miot; Valentin Delpui; Nejm Si-Mohamed; Clémence Niel; Yves Rolland; Brigitte Montes; Soraya Groc; Sophia Rafasse; Anne-Marie Dupuy; Nathalie Gros; Delphine Muriaux; Marie-Christine Picot; Jean Bousquet
Journal:  Allergy       Date:  2021-10-29       Impact factor: 14.710

3.  Post-vaccination SARS-cov-2 infection in nursing home residents, Bordeaux, France.

Authors:  Marion Lartigau; Eric Ouattara; Camille Tumiotto; Harald Wodrich; Laurent Busson; Pascale Trimoulet; Elise Thiel; Mahissata Nouzille; Maria Dubos; Marie-Edith Lafon; Véronique Gilleron; Patrick Dehail; Nathalie Salles; Denis Malvy
Journal:  J Clin Virol       Date:  2022-03-15       Impact factor: 14.481

Review 4.  Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent.

Authors:  Meng Zhang; Yixin Gong; Shunchang Jiao
Journal:  Future Virol       Date:  2022-04-26       Impact factor: 3.015

Review 5.  Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines.

Authors:  Labanya Mukhopadhyay; Nivedita Gupta; Pragya D Yadav; Neeraj Aggarwal
Journal:  Indian J Med Res       Date:  2022-01       Impact factor: 5.274

Review 6.  Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.

Authors:  Maryam Noori; Seyed Aria Nejadghaderi; Shahnam Arshi; Kristin Carson-Chahhoud; Khalil Ansarin; Ali-Asghar Kolahi; Saeid Safiri
Journal:  Rev Med Virol       Date:  2021-07-19       Impact factor: 11.043
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.